Phytosphingosine Hydrochloride + Salicylic Acid

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Phytosphingosine HydrochlorideSalicylic Acid

Administration Routes

Auricular (Otic)TopicalOralOther

Species Affected

Dog 7
Human 7
Cat 2

Most Affected Breeds

Unknown 7
Domestic Shorthair 2
Pit Bull 2
Pug 1
Shar Pei 1
Dog (unknown) 1
Retriever - Labrador 1
Crossbred Canine/dog 1

Most Reported Reactions

Burning sensation of eye 2
Headache 2
Eye irritation 2
Vomiting 1
Anorexia 1
Hind limb ataxia 1
Horner's syndrome 1
Ataxia 1
Lethargy (see also Central nervous system depression in 'Neurological') 1
Application site erythema 1
Pinnae disorder 1
Tongue disorder NOS 1

Outcome Breakdown

Ongoing
9 (56.3%)
Recovered/Normal
6 (37.5%)
Outcome Unknown
1 (6.3%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 3
Distinct breeds in reports 8
Distinct reactions reported 20
Active ingredients on file 2

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Phytosphingosine Hydrochloride + Salicylic Acid Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Phytosphingosine Hydrochloride + Salicylic Acid, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Phytosphingosine Hydrochloride, Salicylic Acid. Reported administration routes include Auricular (Otic), Topical, Oral, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Phytosphingosine Hydrochloride + Salicylic Acid reports are Dog (7 reports), Human (7 reports), Cat (2 reports), with Dog accounting for the largest share. Within those species, Unknown (7), Domestic Shorthair (2), Pit Bull (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Phytosphingosine Hydrochloride + Salicylic Acid are Burning sensation of eye (2), Headache (2), Eye irritation (2), Vomiting (1). Of the 16 reports with a coded outcome, Ongoing is the leading category at 56.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Phytosphingosine Hydrochloride + Salicylic Acid.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial